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Pretreatment HLADQA1-HLADRB1 Testing for the
Prevention of Azathioprine-Induced Pancreatitis in
Inflammatory Bowel Disease: A Prospective Cohort Study
Aze Wilson, MD, PhD1,2,3, Qian Wang, BSc4, Yun-Hee Choi, PhD5, Terry Ponich, MD2, James C. Gregor, MD2, Nilesh Chande, MD2,
Brian Yan, MD2, Michael Sey, MD2, Melanie Beaton, MD2 and Richard B. Kim, MD1,3
INTRODUCTION: Azathioprine-induced pancreatitis is an idiosyncratic and unpredictable response, occurring in up to

7% of azathioprine-exposed patients with inflammatory bowel disease (IBD). The haplotype HLADQA1HLADRB1*07:01A.C is strongly associated with azathioprine-induced pancreatitis in IBD. We aimed
to evaluate whether pretreatment HLADQA1-HLADRB1*07:01A.C screening will reduce the risk of
azathioprine-induced pancreatitis.
METHODS:

Participants with IBD were screened for HLADQA1-HLADRB1*07:01A.C, and participants with a
variant genotype were excluded from azathioprine treatment. Wild-type participants were started on
azathioprine and followed for 3 months. The incidence of pancreatitis was compared with unscreened
historical controls.

RESULTS:

HLADQA1-HLADRB1*07:01A.C screening resulted in an 11-fold reduction in the incidence of
azathioprine-induced pancreatitis (n 5 1/328 or 0.30% vs n 5 13/373 or 3.4%). In propensity scorematched cohorts (age and sex), HLA DQA1-HLADRB1*07:01A.C screening was significantly
associated with a reduction in the incidence of AZA-induced pancreatitis independent of weight,
glucocorticoid exposure, and smoking status (adjusted odds ratio 5 0.075, 95% confidence interval 5
0.01–0.58, P 5 0.01). Up to 45% (n 5 271/599) of participants were excluded from azathioprine
therapy based on the haplotype in the HLADQA1-HLADRB1*07:01A.C-screened cohort.

DISCUSSION:

HLADQA1-HLADRB1*07:01A.C screening reduced the risk of azathioprine-induced pancreatitis;
however, using this strategy to guide the use of azathioprine therapy in IBD may eliminate a large
proportion of patients from being eligible for treatment with azathioprine. In regions where there is
access to other IBD therapies, and given the short-term and long-term toxicities associated with
azathioprine, HLADQA1-HLADRB1*07:01A.C-screening may be a clinically relevant strategy for
enhancing the safe use of azathioprine in IBD. In addition, cost-effectiveness analyses are needed to
further solidify the utility of HLADQA1-HLADRB1*07:01A.C screening in IBD populations.

Clinical and Translational Gastroenterology 2021;12:e00332. https://doi.org/10.14309/ctg.0000000000000332

INTRODUCTION
The complexity of the immune-mediated inﬂammatory bowel
diseases (IBDs), Crohn disease (CD), and ulcerative colitis (UC)
extends beyond disease mechanisms and includes IBD drug
pharmacodynamics. Interindividual responses to IBD medications vary signiﬁcantly, and rates of adverse drug reactions
(ADRs) remain high. Clinicians often rely on a test-and-treat
strategy when selecting the best therapy for their patients because
of the lack of clinical prediction tools. The inability to identify

patients at risk of ADRs suggests a fundamental knowledge gap.
Azathioprine (AZA) therapy has a long history of use in IBD (1).
The need to promote its safe use in this population is ensured by
governmental and private payer health policy requiring patients
with IBD to fail low-cost drugs, such as AZA, before approving
funding for more potent biologic therapies (2–6).
One approach for encouraging the safe use of AZA in IBD is
the increasing advocacy by professional groups and governmental agencies for the use of thiopurine S-methyltransferase
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(TPMT) genetic screening and dose reducing or avoiding its use
in the highest risk patients (7–9).
Unfortunately, there are no tools in clinical practice to identify
individuals at risk of AZA-induced pancreatitis. This is an idiosyncratic and unpredictable response, occurring in up to 7% of
AZA-exposed patients that can lead to patient morbidity, hospitalization, delay in eﬀective IBD management, and result in
substantial additional health-related costs (10–12). Heap et al.
(13) identiﬁed a strong association between a class II HLA gene
region polymorphism (rs2647087) and AZA-induced pancreatitis in an international IBD population. This association was
independently validated in our own retrospective IBD cohort
(14). To date, the utility of screening individuals with IBD for
variation in HLADQA1-HLADRB1 and excluding patients at
high risk of AZA-induced pancreatitis has not been prospectively
assessed. We aimed to evaluate whether HLA DQA1HLADRB1*07:01A.C pretreatment genotype testing in an
adult IBD population before AZA therapy to guide AZA selection
would result in a lower incidence of AZA-induced pancreatitis.

MATERIALS AND METHODS
Subjects

A prospective cohort study was carried out in individuals with
IBD seen at the London Health Sciences Centre, a tertiary care
center aﬃliated with Western University, London, Ontario,
Canada. Participants were assessed for eligibility and enrolled in
the study between March 2017 and February 2020. Eligible participants were greater than 17 years of age, had a histopathological
diagnosis of CD or UC with a need for consideration of AZA
therapy, and had an unknown HLADQA1-HLADRB1 status. In
addition, participants had never received treatment with thiopurine (AZA or 6-mercaptopurine). Participants were excluded
from the study because of the following exclusion criteria: a serum
creatinine greater than 2 times the upper limit of normal, a known

history of liver disease, or an alanine transferase or alkaline
phosphatase greater than 2 times the upper limit of normal, a
leukocyte count less than 3.0 3 109/L, a variant TPMT genotype,
risk factors of pancreatitis (known gallstones, consuming more
than 7 alcoholic beverages weekly, and pancreatitis-associated
medications with the exception of 5-aminosalicylates or glucocorticoids), and missing data pertaining to their IBD diagnosis.
Ethical considerations

The study protocol was approved by the Western University
Health Sciences Research Ethics Board. All subjects provided
written and informed consent.
Haplotype analysis

A single blood sample was collected from each participant for
DNA extraction and determination of their HLA DQA1HLADRB1*07:01A.C haplotype. DNA was extracted from
whole blood using the MagNA Pure Compact instrument (Roche,
Laval, Quebec, Canada). A predesigned TaqMan allelic discrimination assay (Applied Biosystems, Carlsbad, CA) was used to
determine the presence of wild-type and/or variant alleles in HLA
DQA1-HLADRB1*07:01A.C (rs2647087). Each genotyping experiment included 3 positive controls and 1 negative control. Five
percent of samples were genotyped in duplicate. All duplicated
genotypes were in agreement.
Study procedures

High-risk variant carriers (A/C and C/C) were excluded from
AZA therapy. Participants were followed for 3-month duration to
assess for evidence of pancreatitis. AZA-associated pancreatitis
typically occurs within the ﬁrst month of exposure (13,14). AZAinduced pancreatitis was deﬁned as follows: a minimum elevation
in serum lipase 3 times the upper limit of normal with clinical
symptoms of nausea, vomiting, and abdominal pain (15). The

Figure 1. Study enrollment and follow-up. AZA, azathioprine; HLA, human leukocyte antigen; IBD, inflammatory bowel disease; TPMT, thiopurine-Smethyltransferase.
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VOLUME 12 | APRIL 2021 www.clintranslgastro.com

Table 1. Demographic characteristics of patients being evaluated
for azathioprine-induced pancreatitis

Variables
Age, yr, mean (range)

Preemptive
genotyping cohort (n
5 328)

Retrospective
cohort (14) (n 5
373)

P

42.4 (18–86)

41.3 (18–79)

ns

Female sex, n (%)
Weight, kg, mean 6 SD

178 (54.0)

203 (54.4)

ns

79.3 6 20.6

76.6 6 18.8

ns

213 (65.0)

245 (65.7)

ns

134 (40.9)

79 (32.2)

ns

Crohn disease, n (%)
Ileal
Colonic

38 (11.4)

48 (19.6)

ns

Ileocolonic

156 (47.7)

118 (48.2)

ns

Ulcerative colitis, n (%)

The prospective cohort was compared with a group of participants enrolled in a retrospective cohort study published in 2018 by
our group (14). Participants in the retrospective study were AZAexposed patients with IBD genotyped for the HLA DQA1HLADRB1*07:01A.C haplotype after AZA exposure. Subjects
included in this cohort were recruited between 2012 and 2017.
Clinical data including age, sex, weight, smoking, duration of
IBD, drug exposures, hospitalization, and surgeries were collected.
In addition, data pertaining to any diagnosis of AZA-induced
pancreatitis or other AZA-ADR were collected over the 3-month
follow-up period. The primary outcome was the percentage of
clinically diagnosed AZA-induced pancreatitis occurring within
the 3-month observation period between the HLA DQA1HLADRB1*07:01A.C-screened cohort and the unscreened, historical control population.

115 (35.0)

128 (34.3)

ns

Statistical analyses

Pan-colitis

69 (60.0)

81 (63.3)

ns

Left-sided colitis

40 (35.0)

41 (32.0)

ns

6 (5.0)

6 (4.7)

ns

3.67 (11.83)

3.96 (8.42)

ns

Smoking history, n (%)

114 (34.8)

153 (41.0)

ns

5-Aminosalicylate
exposure, n (%)

145 (44.2)

160 (42.9)

ns

Biologic exposure, n
(%)

189 (58.0)

224 (60.1)

ns

Anti-TNF

139 (74.0)

197 (88.0)

0.01

Anti-integrin

33 (17.0)

20 (9.0)

ns

Anti-IL12/23

17 (9.0)

7 (3.0)

ns

92 (28)

71 (18.9)

ns

Statistical analyses were carried out using SPSS version 17.1 and R
version 3.5.3. Given the reported frequency of AZA-induced pancreatitis in the literature (5%), a minimum of 230 participants and 293
participants were needed in the HLA DQA1-HLADRB1*07:01A.Cscreened and control cohorts, respectively, to detect a 90% diﬀerence
in the incidence of pancreatitis assuming a power of 80% with a 2sided P value threshold of 0.05. Descriptive statistics were used to
summarize data obtained for all cohorts. Propensity score matching
was used to balance the distribution of the covariates age and sex
between the HLA DQA1-HLADRB1*07:01A.C-screened and historical control cohorts based on the nearest available matching on the
estimated propensity score method (16). The risk of AZA-induced
pancreatitis associated with HLA DQA1-HLADRB1*07:01A.C
screening vs not screening was evaluated in the matched cohort by
logistic regression analysis with adjustment for weight, glucocorticoid
exposure, and smoking status. A P value ,0.05 was considered signiﬁcant, and the results are expressed as the odds ratio (OR) with 95%
conﬁdence intervals (CIs).

286 (87.2)

301 (80.8)

ns

Proctitis
Median disease
duration, yr
(interquartile range)

a

Combination therapy ,
n (%)
Glucocorticoid
exposure, n (%)
Immunomodulator
exposure, n (%)
Methotrexate

37 (11.3)

55 (14.7)

ns

328 (100.0)

373 (100.0)

ns

55 (16.8)

96 (25.7)

ns

HLA DQA1-DRB1 AA,
n (%)

328 (100.0)

190 (50.9)

—

HLA DQA1-DRB1 AC,
n (%)

0 (0.0)

142 (38.0)

—

HLA DQA1-DRB1 CC,
n (%)

0 (0.0)

41 (11.0)

—

Thiopurine
Surgery, n (%)

HLA, human leukocyte antigen; IL, interleukin; ns, not significant; TNF-a, tumor
necrosis factor a.
a
Combination therapy refers to the simultaneous administration of a biologic
and an immunomodulator (one of methotrexate or azathioprine).

diagnosis of pancreatitis had to be made within 3 months of AZA
exposure in the absence of other causative factors (alcohol, gallstones, and other drugs causing pancreatitis), as detailed in their
medical record at the time of assessment.
American College of Gastroenterology

RESULTS
Figure 1 highlights participant ﬂow through the study. Overall, 599
individuals with IBD (UC, n 5 210; CD, n 5 389) were followed as
part of the prospective cohort study and screened for the HLA
DQA1-HLADRB1*07:01A.C haplotype. Of the 599 participants,
328 had the wild-type A/A haplotype and 271 had a variant haplotype (one of A/C or C/C). Only the wild-type participants from
the HLA DQA1-HLADRB1*07:01A.C-screened cohort received
AZA and were compared with the historical control population (n
5 373). A total of 701 participants were included in the ﬁnal
analyses of the unmatched cohorts (HLA DQA1-HLADRB1*07:
01A.C-screened cohort with an A/A genotype, n 5 328; historical
controls, n 5 373), whereas 656 participants were included in the
ﬁnal analyses of the propensity-matched cohorts (HLA DQA1HLADRB1*07:01A.C-screened cohort with an A/A genotype, n 5
328; historical controls, n 5 328). Demographic data are summarized in Table 1 for the unmatched cohorts. The minor allele
frequency was 0.304 and 0.300 in the HLA DQA1-HLADRB1*07:
01A.C-screened (before exclusion of the variant genotype carriers) and historical control cohorts, respectively. Other baseline
characteristics were similar between the 2 groups except for tumor
necrosis factor-a inhibitor (anti-TNF) exposure, where a greater
number of individuals in the historical control cohort had been
exposed to an anti-TNF agent vs the HLA DQA1-HLADRB1*07:
01A.C-screened group (Table 1).
Clinical and Translational Gastroenterology
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Figure 2. Histograms showing the propensity score distribution in the HLA DQA1-HLADRB1*07:01A.C-screened and unscreened cohorts before and
after matching.

Twenty-three individuals in the HLA DQA1-HLADRB1*07:
01A.C-screened group (with an A/A genotype, n 5 328)
reported nonpancreatitis ADRs that necessitated treatment cessation or dose reduction including hepatotoxicity (4/328), infection (6/328), nausea with or without vomiting (9/328), and
myelosuppression (4/328).
Figure 2 highlights the propensity score distribution in the
HLA DQA1-HLADRB1*07:01A.C-screened and historical control cohorts before and after matching based on the covariates age
and sex. The incidence of AZA-induced pancreatitis in the unmatched cohorts was 0.30% (n 5 1) in the HLA DQA1HLADRB1*07:01A.C-screened cohort and 3.4% (total n 5 13/
373; A/A, n 5 1/190; A/C, n 5 6/142, n 5 6/41) in the historical
control group. After matching the HLA DQA1-HLADRB1*07:
01A.C-screened (n 5 328) and historical control (n 5 328)
using the nearest available matching on the estimated propensity
score method, HLA DQA1-HLADRB1*07:01A.C screening was
signiﬁcantly associated with a reduction in the incidence of AZAinduced pancreatitis independent of weight, glucocorticoid exposure, and smoking status (adjusted OR 5 0.075, 95% CI 5
0.01–0.58, P 5 0.01). Estimates of the regression coeﬃcients in
the logistic regression are shown in Table 2. As expected, there
was no diﬀerence in the incidence of AZA-induced pancreatitis in
the wild-type individuals (A/A) in the HLA DQA1HLADRB1*07:01A.C-screened cohort and the wild-type individuals (A/A) in the historical control cohort (n 5 1 or 0.03% vs n
5 1 or 0.05%; adjusted OR 5 0.574, 95% CI 5 0.036–9.25, P 5
1.00). In the HLADQA1-HLADRB1*07:01A.C-screened cohort,
the time-to-pancreatitis was 21 days in the sole-aﬀected participant. In the historical control population, the median time to
AZA-induced pancreatitis was 25 days (interquartile range, 11
days). All participants who developed pancreatitis required
hospitalization, although the disease course was mild with a
median length of stay of 2 days (interquartile range, 1). Drugs
associated with pancreatitis were an exclusionary criterion, except for 5-aminosalicylates and glucocorticoids. Of the participants who developed pancreatitis, 42.9% (n 5 6/14) were
concurrently on prednisone vs 83.4% (n 5 573/687) of the participants who did not develop pancreatitis. None of the participants who developed pancreatitis were receiving concurrent
therapy with a 5-aminosalicylate at the time of pancreatitis
diagnosis.
Clinical and Translational Gastroenterology

DISCUSSION
Acute pancreatitis remains a prevalent source of hospitalization
and morbidity worldwide (17). Drug-induced pancreatitis, although a less common etiology, is being increasingly recognized
for its importance because of the expanding number of traditional
and homeopathic medications available and the increasing
prevalence of chronic illnesses requiring long-term pharmacologic therapy (18). AZA is a well-established cause of druginduced pancreatitis (18).
There is increasing recognition of the potential value of HLA
DQA1-HLADRB1*07:01A.C screening for identifying individuals at high risk of AZA-induced pancreatitis; however, its role as
a predictive tool for guiding application of AZA therapy in IBD
has not been established (19). In this ﬁrst prospective study, we
show that the incidence of AZA-induced pancreatitis can be
signiﬁcantly reduced in a population screened for variation in
HLADQA1-HLADRB1*07:01A.C, where the haplotype is used
to guide AZA treatment. An 11-fold reduction in the incidence of
AZA-induced pancreatitis is seen in the total population of HLA
DQA1-HLADRB1*07:01A.C-screened participants.
For the purposes of this study, all variant carriers (A/C and C/
C) were treated as though of equal risk of pancreatitis and excluded from AZA therapy. This is despite the fact that in past
retrospective studies, pancreatitis risk is several-fold higher in
homozygous variant carriers (C/C) (13,14). In this study, the
prevalence of the combined variant genotypes (A/C and C/C) was

Table 2. Estimates of the regression coefficients in a logistic
regression model for the age and sex propensity score-matched
cohort (n 5 656)
Variables

Estimate

SE

P

Intercept

23.94

1.22

0.001

HLA DQA1-HLADRB1*07:01A.C-screened

22.59

1.04

0.01

Glucocorticoid exposure

20.56

0.62

0.36

Smoking status

0.16

0.56

0.78

Weight, kg

0.01

0.01

0.29

HLA, human leukocyte antigen.
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45.2% and 49.1% in the HLADQA1-HLADRB1*07:01A.Cscreened and historical control populations, respectively. In
clinical practice, this would translate to 40%–50% of patients
being ineligible for treatment with AZA and requiring alternate
treatments such as methotrexate in CD, tofacitinib in UC, or a
biologic agent for either condition. Some may take issue with the
idea of eliminating AZA from the IBD armamentarium for a large
number of patients. One possible solution, whether HLADQA1HLADRB1*07:01A.C screening is adopted, may be to avoid AZA
therapy in only the highest risk population (those with a C/C
genotype) and accept the slightly higher risk of AZA-induced
pancreatitis (;4%) in those with an A/C genotype. However,
emerging recommendations from professional IBD groups and
regulatory agencies continue to emphasize that AZA be avoided
as monotherapy in patients with IBD because of its associated
drug-related toxicities and increasingly recognized lack of eﬃcacy
(7,20,21). In addition, its use in combination with anti-TNF
agents has been demonstrated to be associated with a substantial
increased risk of infection and malignancy over time (22,23). This
has led to the exploration of the possibility and timing of treatment deescalation whereby AZA or methotrexate is stopped and
the anti-TNF is continued as monotherapy for disease control
(24). These points, as well as the increasing number of novel
agents being approved for use in IBD, highlight the diminishing
role of AZA in IBD and the need to select for its use under the
safest of conditions.
In addition, HLA DQA1-HLADRB1*07:01A.C screening is
relatively inexpensive. The cost of genotyping at our local facility
is $43.75 (CAD) per genotyping test per patient, whereas the costs
associated with hospitalization for acute pancreatitis alone can
extend above $10,000 US ($13,134 CAD) per patient (11,25). In
our population, this would have led to important upfront cost
savings (genotyping costs for 701 patients, $30,668.75 CAD and
estimated hospital costs for 1 acute pancreatitis admission,
$13,134 CAD vs $170,742 CAD for 13 acute pancreatitis hospital
admissions). The costs related to delays in IBD management or
alternate drug selection are unknown. For completeness, we
recognize that a cost-eﬀectiveness analysis is needed to further
solidify the utility of HLA DQA1-HLADRB1*07:01A.C screening in IBD populations for guiding AZA therapy. This would
ensure that genetic screening and the downstream eﬀects on
treatment selection would not lead to higher costs as a trade-oﬀ
for avoiding a signiﬁcant, but less common ADR.
Key strengths of this study are its prospective design and cohorts reﬂective of real-world IBD populations. This enhances the
translatability of this strategy to clinical practice if the appropriate
infrastructure and access are in place. In addition, the rate of
pancreatitis in the historical controls mirrors the rates of AZAinduced pancreatitis seen in other IBD studies and validates that
the ﬁndings in the prospective cohort are not over-inﬂated
(12,26).
Conversely, the use of a historical control for comparison is a
limitation. However, there was little diﬀerence between the patient populations or the standard of IBD care between the 2 cohorts, thus minimizing the risk of chronology bias. In addition,
propensity score matching was used to balance the covariates age
and sex in the matched cohorts to reduce bias.
Accordingly, HLA DQA1-HLADRB1*07:01A.C screening
substantially reduced the risk of pancreatitis during AZA treatment in patients with IBD. However, using this strategy may
eliminate a large proportion of patients with IBD from being
American College of Gastroenterology

eligible for treatment with AZA. In regions where there is access
to other IBD therapies, and given the signiﬁcant short- and longterm toxicities associated with AZA, HLA DQA1-HLADRB1*07:
01A.C screening may be a clinically relevant strategy for enhancing the safe use of AZA in IBD. In addition, cost-eﬀectiveness
analyses are needed to further solidify the utility of HLA DQA1HLADRB1*07:01A.C screening in IBD populations.
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Study Highlights
WHAT IS KNOWN

3 Azathioprine is associated with a drug-induced pancreatitis in
up to 7% of patients with inflammatory bowel disease (IBD).

3 The haplotype, HLADQA1-HLADRB1*07:01A.C, is
3

associated with azathioprine-induced pancreatitis in patients
with IBD.
The impact of screening for the HLADQA1-HLADRB1*07:
01A.C haplotype to guide azathioprine prescribing in IBD is
unknown.

WHAT IS NEW HERE

3 Using the HLADQA1-HLADRB1*07:01A.C haplotype as a
screening tool in patients with IBD to guide the use of
azathioprine significantly reduces the incidence of
azathioprine-induced pancreatitis.

TRANSLATIONAL IMPACT

3 HLADQA1-HLADRB1*07:01A.C screening may be a useful
tool for avoiding an important azathioprine-associated
adverse event.
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